Search

Your search keyword '"Maugère, Pascale"' showing total 11 results
Start Over Author "Maugère, Pascale"
11 results on '"Maugère, Pascale"'

10. Determination of low <SUP>13</SUP>C-glutamine enrichments using gas chromatography–combustion–isotope ratio mass spectrometry

Author

Menand, Corinne, Pouteau, Etienne, Marchini, Sergio, Maugère, Pascale, Krempf, Michel, and Darmaun, Dominique

Abstract

Glutamine is an essential fuel for tissues with high rates of cell replication, such as enterocytes and lymphocytes. Infusion of 13C-labeled glutamine tracers allows for measurement of the rates of production, utilization and oxidation of glutamine’s carbon skeleton in vivo. The use of this tracer, however, has been limited by its high cost and/or the difficulty in measuring low enrichments in biological fluids using conventional gas chromatography–mass spectrometry (GC/MS) techniques. We have developed a method using gas chromatography–combustion–isotope ratio mass spectrometry (GC–C–IRMS) that allows for the determination of low 13C enrichments (down to 0.06 mol.% excess) with a precision of 2% or better, and a within-day and between-day variability better than 5%, in plasma free glutamine. The method was applied to measuring the incorporation of 13C in plasma glutamine over the course of infusion of 13C-labeled acetate in a human subject. © 1997 John Wiley & Sons, Ltd.

Published
1997
Full Text
View/download PDF

11. Glutamine metabolism in Crohn's disease: a stable isotope study.

Author

Bourreille A, Humbert B, Maugère P, Galmiche JP, and Darmaun D

Subjects
Adult, Calorimetry, Indirect, Carbon Isotopes, Case-Control Studies, Deuterium, Female, Humans, Infusions, Intravenous, Intubation, Gastrointestinal, Leucine metabolism, Male, Nutritional Requirements, Oxygen Consumption, Splanchnic Circulation physiology, Crohn Disease metabolism, Glutamine metabolism
Abstract

Aims: To determine whether chronic intestinal inflammation alters glutamine utilization, six 31 +/- 6 yr-old patients with Crohn's disease and an age-matched group of 6 healthy subjects received 7-h intravenous infusions of L-[5,5,5-2H3]leucine, along with an infusion of L-[1-13C]glutamine delivered intravenously for the first 3.5 h, and via a nasogastric tube for the subsequent 3.5 hrs. None of the patients was receiving any nutritional supplement or antiinflammatory drug. All were in remission (Crohn's disease activity index < 150) and in a near-normal nutritional status., Methods: We used plasma 2H3-alpha-ketoisocaproate to determine leucine appearance rate (Ra), and plasma 13C-glutamine and breath 13CO2 to determine glutamine Ra and oxidation, respectively. The fraction of enteral glutamine undergoing uptake in the splanchnic bed was determined from the difference in plasma 13C-glutamine enrichments between the intravenous and nasogastric 13C-glutamine infusion periods., Results: Neither leucine Ra, nor plasma glutamine concentration (526 +/- 40 vs. 530 +/- 50 micromol/l), glutamine Ra (364 +/- 19 vs. 355 +/- 24 micromol kg(-1) h(-1)), or splanchnic glutamine uptake (61 +/- 5 vs. 65 +/- 2%) differed between groups. In both groups, glutamine oxidation rose when the glutamine tracer was supplied enterally, compared with the intravenous route (70 +/- 6 vs. 39 +/- 2% in patients; 69 +/- 2 vs. 38 +/- 1% in controls), but did not differ between groups., Conclusion: When in remission, patients with Crohn's disease have normal rates of proteolysis, and glutamine production, utilization, oxidation, and splanchnic uptake. The data suggest there is no obvious requirement for glutamine in patients with quiescent Crohn's disease.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results